Lab Studies Indicating That Tumors Can Be Eliminated and Immunity Induced to Be Presented to Laser Medicine and Surgery Society.

Business Editors/Health/Medical Writers

KNOXVILLE, Tenn.--(BUSINESS WIRE)--April 10, 2003

Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals, Inc.,

will present findings

Laboratory studies indicating that a light-sensitive drug can kill tumors and induce immunity against additional tumors will be the topic of a presentation in Anaheim by Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) on Sunday, April 13, at the annual meeting of the American Society for Laser Medicine and Surgery.

Craig Dees, Ph.D., CEO of Provectus, will make the presentation at 8:30 a.m. in the Basic Sciences section of the meeting at the Anaheim Hilton.

Dees' studies show that photodynamic therapy and chemoablation of tumors using Provectus' drug PV-10 induce the immune system to remove a second tumor that has not been treated. Chemoablation is the use of chemistry to ablate or kill tumors. Photodynamic therapy combines a light-sensitive drug, such as PV-10, and laser light to destroy cancer cells. Long-lasting immunity to the tumors was produced in laboratory animals in the same way that vaccines produce immunity against infectious agents.

Dee's presentation will also include a case study, in which a veterinarian using PV-10 to treat four mast cell tumors in a dog induced the removal of more than 20 large, untreated tumors.

"This is a very promising discovery. It suggests that practical cancer treatments may be able to be designed that stimulate natural defenses to prevent the recurrence of tumors after treatment at the primary site and also to kill cancer cells that migrate elsewhere in the body," Dees said.

Provectus Pharmaceuticals licenses and sells products in three sectors of the health-care industry: 1.) prescription medications and treatment, 2.) medical devices, and 3.) over-the-counter (OTC) pharmaceuticals. Prescription drug products and devices treat diseases of the skin and many types of cancer. OTC products address complementary markets, primarily those involving skin care and comfort.

The company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; Telephone: [phone]. For more information, contact the company at [e-mail] or visit the corporate Web site: www.provectuscorp.com.

Forward-Looking Statements

This news release may contain forward-looking statements. All statements other than statements of historical fact made in this news release are forward-looking statements. Words such as "intends," "expects," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements. Forward-looking statements reflect management's current assumptions, beliefs, and expectations and are subject to risks and uncertainties, including those discussed in the company's filings with the Securities and Exchange Commission, that could cause actual results to differ materially from historical or anticipated results. The forward-looking statements are made as of the date of this news release, and Provectus Pharmaceuticals Inc. assumes no obligation to update the forward-looking statements after the date hereof whether as a result of new information or events, changed circumstances, or otherwise, except as required by law.